{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:14:04Z","timestamp":1788326044707,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Pharmacol"],"published-print":{"date-parts":[[2002,3,1]]},"DOI":"10.1124\/mol.61.3.495","type":"journal-article","created":{"date-parts":[[2003,1,15]],"date-time":"2003-01-15T23:12:39Z","timestamp":1042672359000},"page":"495-506","source":"Crossref","is-referenced-by-count":93,"title":["Midazolam Oxidation by Cytochrome P450 3A4 and Active-Site Mutants: an Evaluation of Multiple Binding Sites and of the Metabolic Pathway That Leads to Enzyme Inactivation"],"prefix":"10.1016","volume":"61","author":[{"given":"Kishore K.","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You Qun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy L.","family":"Domanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Halpert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","published-online":{"date-parts":[[2002,3,1]]},"reference":[{"key":"2019081414074776000_61.3.495.1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.050406897"},{"key":"2019081414074776000_61.3.495.2","doi-asserted-by":"publisher","DOI":"10.2174\/1389200013338612"},{"key":"2019081414074776000_61.3.495.3","first-page":"585","article-title":"Dual role of human cytochrome P450 3A4 residue Phe-304 in substrate specificity and cooperativity.","volume":"293","author":"Domanski","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"2019081414074776000_61.3.495.4","doi-asserted-by":"publisher","DOI":"10.1021\/bi010758a"},{"key":"2019081414074776000_61.3.495.5","doi-asserted-by":"publisher","DOI":"10.1006\/abbi.1997.0525"},{"key":"2019081414074776000_61.3.495.6","doi-asserted-by":"crossref","unstructured":"Eiselt R Domanski TL Zibat A Mueller R P-Siedel E Hustert E Zanger UM Brockmoller J Klenk H-P Meyer UA (2001) Identification and functional characterization of eight CYP3A4 protein variants Pharmacogenet 11:447\u2013458.","DOI":"10.1097\/00008571-200107000-00008"},{"key":"2019081414074776000_61.3.495.7","first-page":"139","article-title":"Systematic screening for pharmacokinetic interactions during drug development.","volume":"34","author":"Fuhr","year":"1996","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2019081414074776000_61.3.495.8","first-page":"940","article-title":"Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450.","volume":"24","author":"Ghosal","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"2019081414074776000_61.3.495.9","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(94)90543-6"},{"key":"2019081414074776000_61.3.495.10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0021-9258(18)48462-1","article-title":"Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences.","volume":"267","author":"Gotoh","year":"1992","journal-title":"J Biol Chem"},{"key":"2019081414074776000_61.3.495.11","doi-asserted-by":"crossref","unstructured":"Guengerich FP (1995) Human cytochrome P450 enzymes. in Cytochrome P450, ed Oritz de Montellano PR (Plenum Press, New York), pp 473\u2013535.","DOI":"10.1007\/978-1-4757-2391-5_14"},{"key":"2019081414074776000_61.3.495.12","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.9.5396"},{"key":"2019081414074776000_61.3.495.13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.12.6636"},{"key":"2019081414074776000_61.3.495.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-2126(01)00134-4"},{"key":"2019081414074776000_61.3.495.15","doi-asserted-by":"publisher","DOI":"10.1021\/bi970182i"},{"key":"2019081414074776000_61.3.495.16","doi-asserted-by":"publisher","DOI":"10.1021\/bi992765t"},{"key":"2019081414074776000_61.3.495.17","doi-asserted-by":"publisher","DOI":"10.1006\/abbi.1999.1578"},{"key":"2019081414074776000_61.3.495.18","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018877803319"},{"key":"2019081414074776000_61.3.495.19","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.10.5014"},{"key":"2019081414074776000_61.3.495.20","doi-asserted-by":"publisher","DOI":"10.1021\/bi9715627"},{"key":"2019081414074776000_61.3.495.21","first-page":"89","article-title":"Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4.","volume":"36","author":"Kronbach","year":"1989","journal-title":"Mol Pharmacol"},{"key":"2019081414074776000_61.3.495.22","doi-asserted-by":"publisher","DOI":"10.1038\/86882"},{"key":"2019081414074776000_61.3.495.23","first-page":"798","article-title":"Specific dehydrogenation of 3-methylindole and epoxidation of naphthalene by recombinant human CYP2F1 expressed in lymphoblastoid cells.","volume":"27","author":"Lanza","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"2019081414074776000_61.3.495.24","first-page":"137","article-title":"Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone.","volume":"8","author":"Maenpaa","year":"1998","journal-title":"Pharmacogenetics"},{"key":"2019081414074776000_61.3.495.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0736-4679(97)00022-X"},{"key":"2019081414074776000_61.3.495.26","first-page":"618","article-title":"Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms.","volume":"292","author":"Perloff","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"2019081414074776000_61.3.495.27","first-page":"154","article-title":"Evidence supporting mechanism-based inactivation of CYP3A by midazolam.","volume":"8","author":"Podoll","year":"1995","journal-title":"ISSX Proc"},{"key":"2019081414074776000_61.3.495.28","doi-asserted-by":"publisher","DOI":"10.1006\/abbi.1999.1599"},{"key":"2019081414074776000_61.3.495.29","doi-asserted-by":"publisher","DOI":"10.1006\/abbi.2001.2401"},{"key":"2019081414074776000_61.3.495.30","first-page":"493","article-title":"Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by \u03b1-naphthoflavone.","volume":"33","author":"Schwab","year":"1988","journal-title":"Mol Pharmacol"},{"key":"2019081414074776000_61.3.495.31","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M008799200"},{"key":"2019081414074776000_61.3.495.32","doi-asserted-by":"publisher","DOI":"10.1021\/bi00187a009"},{"key":"2019081414074776000_61.3.495.33","doi-asserted-by":"crossref","unstructured":"Szklarz GD Halpert JR (1997) Molecular modeling of cytochrome P450 3A4 J Comput Aided Mol Des 11:265\u2013272.","DOI":"10.1023\/A:1007956612081"},{"key":"2019081414074776000_61.3.495.34","first-page":"594","article-title":"Use of the steroid derivative RPR 106541 in combination with site-directed mutagenesis for enhanced cytochrome P-450 3A4 structure\/function analysis.","volume":"290","author":"Stevens","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"2019081414074776000_61.3.495.35","doi-asserted-by":"crossref","unstructured":"Thummel KE Wilkinson GR (1998) In vitro and in vivo drug interactions involving human CYP3A4 Annu Rev Pharmacol Toxicol 38:389\u2013430.","DOI":"10.1146\/annurev.pharmtox.38.1.389"},{"key":"2019081414074776000_61.3.495.36","doi-asserted-by":"publisher","DOI":"10.1021\/bi962359z"},{"key":"2019081414074776000_61.3.495.37","doi-asserted-by":"publisher","DOI":"10.1021\/bi980895g"},{"key":"2019081414074776000_61.3.495.38","first-page":"360","article-title":"Human cytochrome P-450 3A4 in vitro drug-drug interaction patterns are substrate-dependent.","volume":"28","author":"Wang","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"2019081414074776000_61.3.495.39","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(00)80408-6"},{"key":"2019081414074776000_61.3.495.40","doi-asserted-by":"publisher","DOI":"10.1021\/tx000218z"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/mol.61.3.495","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T18:35:58Z","timestamp":1732732558000},"score":1,"resource":{"primary":{"URL":"http:\/\/molpharm.aspetjournals.org\/lookup\/doi\/10.1124\/mol.61.3.495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3,1]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2002,3,1]]},"published-print":{"date-parts":[[2002,3,1]]}},"alternative-id":["10.1124\/mol.61.3.495"],"URL":"https:\/\/doi.org\/10.1124\/mol.61.3.495","relation":{},"ISSN":["0026-895X","1521-0111"],"issn-type":[{"value":"0026-895X","type":"print"},{"value":"1521-0111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,3,1]]}}}